OND Stock Overview
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.077 |
| 52 Week High | kr0.99 |
| 52 Week Low | kr0.076 |
| Beta | -0.60 |
| 1 Month Change | -82.53% |
| 3 Month Change | -87.03% |
| 1 Year Change | -91.62% |
| 3 Year Change | -99.41% |
| 5 Year Change | -99.34% |
| Change since IPO | -98.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| OND | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -79.5% | -1.2% | 1.7% |
| 1Y | -91.6% | -23.0% | 2.3% |
Price Volatility
| OND volatility | |
|---|---|
| OND Average Weekly Movement | 27.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: OND's weekly volatility has increased from 16% to 28% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 57 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Oncopeptides AB (publ) Fundamentals Summary
| OND fundamental statistics | |
|---|---|
| Market cap | €27.31m |
| Earnings (TTM) | -€21.40m |
| Revenue (TTM) | €3.03m |
9.0x
P/S Ratio-1.3x
P/E RatioIs OND overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OND income statement (TTM) | |
|---|---|
| Revenue | kr35.22m |
| Cost of Revenue | -kr1.08m |
| Gross Profit | kr36.30m |
| Other Expenses | kr285.41m |
| Earnings | -kr249.11m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | -2.52 |
| Gross Margin | 103.06% |
| Net Profit Margin | -707.30% |
| Debt/Equity Ratio | 187.5% |
How did OND perform over the long term?
See historical performance and comparison